Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of PF-05280014 vs Trastuzumab-US in Healthy Male Volunteers
NCT02015156Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2014
- Primary completion
- Feb 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trastuzumab-qyyp in breast cancer and gastric cancer (GC) (2 arms), sponsored by Pfizer. Primary endpoint: Incidence of body temperature greater than or equal to 38.0 degrees Celsius at 24 hours. Started Jan 2014; status: completed.
02
Drugs
trastuzumab-qyyp
03
Conditions
breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT02015156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015156.